SCHEMBL87028

SCHEMBL87028

O=C(NC12COC(Cn3c1nc(C(=O)NO)c(O)c3=O)C2)OCc1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.34
ADAMTS4 O75173 1/20 0.33
ADAMTS5 Q9UNA0 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MAOB P27338 1/20 0.32
CTSK P43235 4/20 0.32
CTSB P07858 3/20 0.32
CTSS P25774 3/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
CASP1 P29466 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13691434 0.88 ROCK2 (0.39) MAOBCTSKALDH1A1SMN1; SMN2ADORA2A
SCHEMBL63287 0.82 KCNH2 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL63543 0.81 KCNH2 (0.42) ALDH1A1TSHRSMN1; SMN2
SCHEMBL52276 0.81 ROCK2 (0.36) MAOBCTSKCTSBCTSSSMN1; SMN2
SCHEMBL51543 0.81 ROCK2 (0.38) MAOBCTSKCTSBCTSSSMN1; SMN2
SCHEMBL13691651 0.76 CTSK (0.33) CTSKCTSBCTSSADORA2AADORA1
SCHEMBL62481 0.75 KCNH2 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL62281 0.74 KCNH2 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL63621 0.73 ROCK2 (0.38) CTSKCTSBCTSSADORA2AADORA1
SCHEMBL52246 0.73 HPGD (0.37) CTSKCTSBCTSSADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG ATM 967/4885ADAMTS4 4065/4885ADAMTS5 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.